Clinical research
Being tested in people in registered clinical trials. Being in trials is not evidence that a treatment works or is safe.
本试验正在测试什么
This is the study that made Casgevy an approved medicine. Participants with severe sickle cell disease had their own blood stem cells edited and returned. The main question was whether they would stop having the severe pain crises that define the disease — and for the large majority, they did.
An open-label, single-arm, multi-site Phase 2/3 study of autologous CRISPR-Cas9-modified CD34+ cells (CTX001, later exagamglogene autotemcel) in patients aged 12–35 with severe sickle cell disease. The primary endpoint was freedom from severe vaso-occlusive crises for at least 12 consecutive months. Results supported approvals by the MHRA, FDA and EMA.
Sources
- New England Journal of Medicine · 2024
Exagamglogene autotemcel for severe sickle cell disease ↗
试验结果意味着什么，又不意味着什么
早期试验结果来自少量参与者和较短的随访周期，随着人数增加和时间延长，结论可能发生变化。正在招募、进行中甚至已完成的试验，并不代表某种疗法已被证实有效。入组标准十分严格，是否符合条件由试验机构决定，而非由网站判断。